famitinib
An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs.
| Code name: | SHR-1020 SHR1020 |
|---|---|
| Chemical structure: | 4H-pyrrolo(3,2-c)pyridin-4-one, 5-(2-(diethylamino)ethyl)-2-((5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-1,5,6,7-tetrahydro-3-methyl- |